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This prospective study was conducted with the Korean Cancer Study Group to evaluate the efficacy and safety of cetuximab
combined with modified FOLFOX6 (mFOLFOX6) as first-line treatment in recurrent or metastatic gastric cancer and to identify
potential predictive biomarkers. Patients received cetuximab 400mgm
 2 at week 1 and 250mgm
 2 weekly thereafter until disease
progression. Oxaliplatin (100mgm
 2) and leucovorin (100mgm
 2) were administered as a 2-h infusion followed by a 46-h
continuous infusion of 5-fluorouracil (2400mgm
 2) every 2 weeks for a maximum of 12 cycles. Biomarkers potentially associated
with efficacy were analysed. Among 38 evaluable patients, confirmed response rate (RR) was 50.0% (95% CI 34.1–65.9). Median
time-to-progression (TTP) was 5.5 months (95% CI 4.5–6.5) and overall survival (OS) 9.9 months. Eleven patients having tumour
EGFR expression by immunohistochemistry with low serum EGF and TGF-a levels showed a 100% RR compared to 37.0% in the
remaining 27 patients (Po0.001). Moreover, ligand level increased when disease progressed in seven out of eight patients with EGFR
expression and low baseline ligand level. No patient exhibited EGFR amplification or K-ras mutations. Gastric cancer patients with
EGFR expression and low ligand levels had better outcomes with cetuximab/mFOLFOX6 treatment.
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Gastric cancer is one of the most common cancers worldwide with
a particularly high incidence in Asian countries including Korea
(Shin et al, 2004; Kamangar et al, 2006). Regardless of geographical
incidence, gastric cancer is also associated with high mortality as
many patients present with locally advanced or metastatic disease,
and treatment options are limited (Kamangar et al, 2006). Thus, it
is one of the more therapeutically challenging cancers for
oncologists. Although recent efforts to improve the treatment of
gastric cancer have shown positive results, the outcome of
advanced disease is still disappointing (Van Cutsem et al, 2006;
Cunningham et al, 2008). Targeted agents are therefore being
investigated in an effort to improve survival of gastric cancer
patients (Tabernero et al, 2005).
Cetuximab (Erbitux; Merck KGaA, Darmstadt, Germany) is
an immunoglobulin G1 monoclonal antibody that binds the
epidermal growth factor receptor (EGFR) with high affinity, which
competitively blocks ligand binding, inhibits tyrosine kinase
activation and results in receptor downregulation (Mendelsohn
and Baselga, 2003). Cetuximab has shown promising results in
EGFR-expressing metastatic colorectal cancer in both the first-line
setting and in patients with refractory disease (Cunningham et al,
2004; Jonker et al, 2007; Van Cutsem et al, 2007). Cetuximab plus
chemotherapy (irinotecan/5-FU/leucovorin (FOLFIRI) and weekly
oxaliplatin/5-FU/leucovorin (FUFOX)) has also shown favourable
results as a first-line treatment of advanced gastric or gastro-
esophageal junction adenocarcinoma in phase II studies (Lordick
et al, 2007; Pinto et al, 2007).
Recent biomarker studies suggest that selection of patients
according to their biomarker status may improve treatment
outcomes. Biomarker analysis of cetuximab in colorectal cancer
has identified potential biomarkers such as EGFR gene amplifica-
tion and K-ras mutations that may guide treatment decisions
(Moroni et al, 2005; Khambata-Ford et al, 2007; Sartore-Bianchi
et al, 2007; Zhang et al, 2007; Bokemeyer et al, 2008; Cappuzzo
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set al, 2008; Lievre et al, 2008; Van Cutsem et al, 2008; Tejpar et al,
2008b). The additional activity of cetuximab combined with
chemotherapy was limited to K-ras wild-type colorectal cancers
(Bokemeyer et al, 2008; Van Cutsem et al, 2008). Other potential
biomarkers of cetuximab activity in colorectal cancer include
EGFR ligands (epiregulin and amphiregulin) and polymorphisms
in EGFR, EGF, and Fc fragment of IgG receptor (Khambata-Ford
et al, 2007; Zhang et al, 2007; Graziano et al, 2008; Tejpar et al,
2008a). However, there is only limited data regarding biomarkers
in gastric cancer patients treated with cetuximab (Rojas Llimpe
et al, 2007).
This study evaluated cetuximab in combination with modified
FOLFOX6 (mFOLFOX6), which is one of the most widely used
first-line chemotherapy regimens in Korea, in previously untreated
patients with advanced gastric cancer. Moreover, to identify
candidate biomarkers for optimal patient selection of cetuximab/
mFOLFOX6 treatment in gastric cancer, we have investigated
biomarkers that may be associated with efficacy.
PATIENTS AND METHODS
Study design
This study was a prospective multicentre phase II study performed
in eight centres of the Korean Cancer Study Group (KCSG). The
primary end point was overall response rate according to the
Response Evaluation Criteria in Solid Tumours (RECIST)
(Therasse et al, 2000). The secondary end points included time-
to-progression, overall survival, toxicity, and pharmacogenomic
analysis. Written informed consent was received prior to study
entry. The study protocol was reviewed and approved by the
Institutional Review Boards at the participating institutions.
Recommendations of the Declaration of Helsinki for biomedical
research involving human subjects were also followed.
Patients and treatments
The main inclusion criteria were age X18 years, Eastern
Cooperative Oncology Group (ECOG) performance status (PS)
p2, histologically confirmed adenocarcinoma of the stomach,
recurrent or metastatic disease, no prior chemotherapy, radio-
therapy, immunotherapy, or EGFR pathway-targeting therapy
(prior adjuvant chemotherapy completed 412 months from the
study medication was permitted), adequate bone marrow, hepatic,
and renal function, and at least one measurable lesion. Exclusion
criteria included intestinal obstruction or impending obstruction,
active tumour bleeding, interstitial pneumonitis or symptomatic
pulmonary fibrosis, pregnant or breastfeeding patients, other
serious diseases, and peripheral neuropathy of grade 1.
Patients received an initial dose of cetuximab 400mgm
 2 followed
by weekly doses of 250mgm
 2. Modified FOLFOX6 comprised
of oxaliplatin 100mgm
 2 and leucovorin 100mgm
 2 given intra-
venously over 2h on day 1 followed by a 46h infusion of
5-fluorouracil (5-FU) 2400mgm
 2, which was repeated every 2
weeks. Patients received a maximum of 12 cycles of mFOLFOX6.
Cetuximab was continued as a monotherapy until disease progression.
Response evaluation was performed following the RECIST criteria
(Therasse et al, 2000). Computed tomography (CT) scans were
performed every 6 weeks during the cetuximab/mFOLFOX6 treat-
ment period and every 8 weeks afterwards. Complete or partial
responses were confirmed with CT scans taken at least 4 weeks apart.
Adverse events were assessed using National Cancer Institute
Common Terminology Criteria for Adverse Events version 3.0.
Biomarker analysis
Biomarker analysis of tumour was performed with formalin-fixed
paraffin-embedded tissue blocks. In relapsed cases, tissue specimen
obtained after recurrence was required for the study entry.
However, in two cases found to have inadequate tumour left in
these blocks, tissue from prior gastrectomy was used. Tissue of
origin was stomach in 34, liver in three, and abdominal soft tissue
in one. Immunohistochemistry (IHC) of thymidylate synthase,
thymidine phosphorylase (TP), and excision repair cross-comple-
mentation group 1 (ERCC1) was performed as described in
Supplementary Table 1. Expression of EGFR and HER2 was
determined using the PharmDx kit (DAKO, Carpinteria, CA, USA)
and the HercepTest kit (DAKO), respectively, according to the
manufacturer’s instructions. Staining was carried out using an
Autostainer 360 (Lab Vision, Fremont, CA, USA). For quantitative
scoring of IHC, an IHC score (0–300) was derived by multiplying
the staining intensity (0, 1, 2, 3) by the percentage of positive cells
(0–100). Gene amplifications of EGFR and HER2 were detected by
fluorescence in situ hybridization (FISH) using LSI EGFR/CEP 7
Dual Color Probe (Vysis, Des Plaines, IL, USA) for EGFR and
PathVysion (Vysis) for HER2 following the manufacturer’s
instructions. Blinded scoring of IHC and FISH was performed by
two pathologists (MAK and WHK). For the mutational analysis,
only the areas in which cancer cells occupied more than 60% of the
total area assessed by H&E slide review were selected for DNA
extraction. Direct sequencing of nested polymerase chain reaction
(PCR) products of K-ras exons 1 and 2 was performed
using primers listed in Supplementary Table 2. Enzyme-linked
immunosorbent assay (ELISA) of serum samples acquired before
treatment and at the time of disease progression was performed
using commercially available kits following the manufacturer’s
instructions for the following markers: EGFR extracellular domain
(Calbiochem, San Diego, CA, USA), EGF (R&D Systems, Minnea-
polis, MN, USA), TGF-a (R&D Systems), and amphiregulin (R&D
Systems). Samples were assayed in duplicate.
Statistical analysis
This study was designed to test the hypothesis that the response
rate of the study treatment would be 70% (H1), which is
significantly different from 40% (H0). The H0 and H1 values were
demanded by the Korean Food and Drug Administration for
approval of the study. Sample size was determined following
Simon 2-stage design with a type I and II error of 5% each (Simon,
1989). Fourteen patients were enrolled in the first stage. When six
or more responses were observed, the second stage was initiated to
enroll 20 additional patients for a total of 34 patients. To reject H0,
19 responses were required among 34 patients. Assuming a 15%
dropout rate, the total number of patients needed for the study
was 40.
For the selection of a cutoff point for the IHC score and ligand
level, a receiver operating characteristic curve analysis was utilised
in which the IHC score was also regarded as a continuous variable.
The IHC score and ligand level with the highest sensitivity and
specificity for response was chosen as the cutoff. Statistical analysis
of biomarker status and response rate was carried out using
Pearson’s w
2 test or Fisher’s exact test. Serum ligand levels were
compared using the Kruskal–Wallis test or Mann–Whitney
U-test. Multivariate analysis of response was performed with the
backward stepwise logistic regression model. Median durations of
TTP and OS were calculated using the Kaplan–Meier method.
Comparisons of TTP and OS were made with log-rank tests.
Multivariate analysis of TTP and OS were carried out using the
backward stepwise Cox regression model. In the multivariate
analysis, biomarkers with Po0.20 were included as covariates. To
adjust for baseline characteristics, sex, age, ECOG PS (0 vs 1–2),
Lauren classification, and additional characteristics with Po0.20
(site and number of involved organs) were also included. Two
sided P-values of less than 0.05 were considered significant. All
analyses were performed using SPSS for Windows, version 12.0
(SPSS Inc., Chicago, IL, USA).
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sRESULTS
Patients
Between December 2006 and June 2007, 40 patients with recurrent
or metastatic gastric cancer were enrolled into the study. Baseline
patient and disease characteristics are presented in Table 1. Of the
40 patients enrolled, one patient withdrew his consent and refused
any further follow-up immediately following completion of 1st
cycle of mFOLFOX6 treatment and another patient developed
gastric perforation 1 week after treatment initiation the cause of
which was unclear. These two patients are excluded from
the efficacy analysis and the former patient is also excluded from
the safety analysis. Therefore, 38 patients were evaluable for
response and 39 patients assessable for safety. At the time of data
cutoff at the end of January 2008, four patients were still receiving
cetuximab maintenance monotherapy. Median dose intensities
of cetuximab, oxaliplatin, and 5-fluorouracil were 100% (range
66.6–100%), 92.3% (48.0–100%), and 92.2% (55.4–100%),
respectively.
Efficacy and safety
Among the 38 evaluable patients, the best overall response was
partial response (PR) in 19 patients (50.0%, 95% confidence
interval (CI) 34.1–65.9). All PRs were confirmed after 4 weeks.
Stable disease (SD) was observed in 16 patients (42.1%, 95% CI
26.4–57.8), and progressive disease (PD) in three patients (7.9%,
95% CI 0–16.5). The disease control rate (PR þ SD) was 92.1%
(95% CI 83.5–100). In the intent-to-treat analysis, response rate
and disease control rate were 47.5% (95% CI 32.0–63.0) and 87.5%
(95% CI 77.3–97.7), respectively. Among the 16 patients with SD,
there were two unconfirmed responders (one withdrawal of
consent after obtaining a PR, and one death unrelated to disease
or treatment prior to confirmation of the response). These two
unconfirmed responders are included in the responder group in
the following biomarker analysis. Median time-to-progression was
5.5 months (95% CI: 4.5–6.5) (Supplementary Figure 1A). Until
January 2008 (median duration of follow-up 9.8 months), 18 death
events occurred among 38 evaluable patients. Median overall
survival was 9.9 months (Supplementary Figure 1B).
Cetuximab in combination with mFOLFOX6 was generally well-
tolerated with Grade X3 adverse events reported as expected for
this treatment combination. Fifteen patients (38.5%) experienced
any kind of grade 3 or 4 adverse event. The most commonly
reported Grade 3/4 adverse events were neutropenia, diarrhoea,
stomatitis, and rash (Supplementary Table 3). One adverse event
related to treatment (febrile neutropenia) led to death.
Patients who did not develop skin rash (five patients) had
shorter TTP (P¼0.011, median 1.3 vs 5.6 months) and OS
(P¼0.008, median 2.4 months vs not reached) compared to the
patients who developed any grade of skin rash (33 patients).
Response rates were 20.0 and 54.5%, respectively (P¼0.34). No
significant difference in TTP or OS was seen between the grades of
rash.
Biomarker analyses
Among the biomarkers tested, low serum levels of EGF
(o667pgml
 1) and TGF-a (o14pgml
 1) were significantly
associated with a higher response rate (Table 2). Serum EGF level
was significantly different according to best overall response and
TGF-a level showed a similar trend (Figure 1). In the multivariate
analysis, low serum EGF level was significantly associated with
response (adjusted HR 11.8, 95% CI 1.8–75.4; P¼0.009). No
marker was significantly associated with TTP in the univariate
analysis (Table 2). Nevertheless, EGFR expression in the tumour
was significantly associated with longer TTP in the multivariate
analysis (adjusted HR 0.23, 95% CI 0.086–0.63; P¼0.004). In the
univariate analysis of OS, low TP and ERCC1 expression in
the tumour was associated with longer OS (Table 2). In the
multivariate analysis, only a low tumour TP expression was
associated with longer survival (adjusted HR 0.26, 95% CI 0.097–
0.70; P¼0.008).
To identify a patient subgroup that is most likely to benefit from
the treatment, combinations of biomarkers were evaluated.
Interestingly, all of the patients (N¼11) having EGFR tumour
expression detected by immunohistochemistry together with
low levels of both serum EGF (o667pgml
 1) and TGF-a
(o14pgml
 1) showed a response. Response rate in the remaining
patients (N¼27) was 37.0% (Po0.001). Serum EGF and TGF-a
levels were lower in responders with EGFR expression compared to
non-responders, whereas no association between serum ligand
level and response was found in patients with negative EGFR
expression (Supplementary Figure 2). TTP (P¼0.47; median 7.2 vs
5.0 months, respectively) and OS (P¼0.22; not reached vs 7.6
months, respectively) were not significantly different in the
univariate analysis (Figure 2). Nonetheless, after adjusting for
clinical factors (age, sex, PS, Lauren classification, site and number
of involved organs), TTP (adjusted HR 0.28, 95% CI 0.09–0.82;
P¼0.020) and OS (adjusted HR 0.16, 95% CI 0.04–0.68; P¼0.013)
were also significantly longer in these patients with EGFR
expression and low levels of ligands. Moreover, among eight
Table 1 Patient and disease characteristics at baseline
Characteristic Number of patients (N¼40) %
Sex
Male 30 75.0
Female 10 25.0
Age, years
Median 55
Range 33–74
Performance status (ECOG)
0 7 17.5
1 29 72.5
2 4 10.0
Disease status
Relapsed 5 12.5
Adjuvant chemotherapy 3
No adjuvant chemotherapy 2
Initially metastatic 35 87.5
Location
Proximal 5 12.5
Middle 4 10.0
Distal 26 65.0
Diffuse 5 12.5
Lauren classification
Intestinal 12 30.0
Diffuse 28 70.0
Number of organs involved
1 5 12.5
2 7 17.5
3 17 42.5
4 7 17.5
X5 4 10.0
Site of metastasis
Lymph node 36 90.0
Peritoneum 21 52.5
Liver 16 40.0
Others (lung, bone, and so on) 9 22.5
ECOG, Eastern Cooperative Oncology Group.
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spatients with follow-up serum samples collected at the time of
disease progression, seven patients showed elevation of EGF or
TGF-a level above the cutoff values (Figure 3).
Although recent studies have shown a significant association
between the response to cetuximab treatment and EGFR amplifi-
cation or K-ras mutations in colorectal cancer, none of the patients
in the present study exhibited increased EGFR gene copy number
(EGFR/CEP7 42.0) or K-ras mutations.
DISCUSSION
Targeting EGFR with monoclonal antibodies or tyrosine kinase
inhibitors has improved treatment strategies against cancer during
the past few years. Patient selection strategy for these agents is an
important issue. Randomised studies of cetuximab combined with
chemotherapy in the first-line treatment of colorectal cancer
clearly showed that the benefit of adding cetuximab was limited to
Table 2 Univariate analyses of biomarker and treatment outcomes
Criteria
(No. of patients)
Responders
(%) P-value
Median
TTP (mo) P-value
Median OS
(mo) P-value
Tumour expression (IHC)
TS
a o25 (13) 9 (69.2) 0.21 4.8 0.78 N/R 0.15
425 (25) 12 (48) 5.5 8.2
TP
a o25 (20) 13 (65) 0.20 7.2 0.10 N/R 0.021
425 (18) 8 (44.4) 3.8 7.0
ERCC1
a o130 (16) 11 (68.8) 0.15 7.2 0.60 N/R 0.022
4130 (22) 10 (45.5) 5.0 7.0
EGFR
b ( ) (12) 5 (41.7) 0.25 2.8 0.18 6.1 0.33
1+ in X10% (26) 16 (61.5) 5.9 N/R
HER2
b 0/1+ (32) 16 (50) 0.20 5.3 0.20 9.9 0.47
2+/3+ (6) 5 (83.3) 7.2 N/R
Gene copy number (FISH)
HER2/CEP17 o2.0 (33) 18 (54.5) 1.0 5.3 0.18 9.9 0.66
42.0 (5) 3 (60) N/R N/R
Serum protein level (ELISA)
EGFR (ngml
 1) o41.9 (13) 6 (46.2) 0.42 5.5 0.73 5.6 0.12
441.9 (25) 15 (60) 5.5 N/R
EGF (pgml
 1) o667 (20) 15 (75) 0.01 7.6 0.88 N/R 0.51
4667 (18) 6 (33.3) 5.0 7.6
TGF-a (pgml
 1) o14 (21) 15 (71.4) 0.03 5.9 0.47 N/R 0.31
414 (17) 6 (35.3) 4.8 7.6
Amphiregulin (pgml
 1) o1.14 (16) 7 (43.8) 0.22 5.0 0.89 6.1 0.34
41.14 (22) 14 (63.6) 7.2 N/R
CEP, chromosome enumerator probe; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; ELISA, enzyme-linked immunosorbent assay; ERCC1, excision
repair cross-complementation group 1; FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; mo, months; N/R,
not reached; OS, overall survival; TGF, transforming growth factor; TP, thymidine phosphorylase; TS, thymidylate synthase; TTP, time-to-progression.
aNumbers in the criteria
denote IHC scores derived from staining intensity and percentage of positive cells.
bIHC score cutoff for EGFR was 7.5 which was identical to 1+ staining in 10% or more cancer
cells. The cutoff for HER2 was 15, which was identical to 2+ staining in at least 10% of cells.
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Figure 1 Baseline serum EGF (A) and TGF-a (B) levels according to the best overall response. Bars indicate median values. P-value by Kruskal–Wallis
test. Abbreviations: EGF, epidermal growth factor; TGF, transforming growth factor; PR, partial response; SD, stable disease; PD, progressive disease.
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sK-ras wild-type cancers (Bokemeyer et al, 2008; Van Cutsem et al,
2008). In contrast, the addition of cetuximab to FOLFOX-4 had a
detrimental effect on response and progression-free survival in
K-ras mutant tumours in the OPUS trial (Bokemeyer et al, 2008).
High EGFR gene copy number has been associated with better
response to cetuximab or panitumumab (Moroni et al, 2005;
Sartore-Bianchi et al, 2007; Cappuzzo et al, 2008). However, no
patient had K-ras mutation or increased EGFR gene copy number
in this study. Previous studies performed in large number of
patients also demonstrate that K-ras mutation or increased EGFR
gene copy number is an uncommon genetic event in gastric cancer
(Lee et al, 2003; Kim et al, 2008). These data suggest that a
biomarker application needs to be based on the specific type of
cancer.
In this study, we have failed to show a pre-specified improve-
ment of response rate by addition of cetuximab to mFOLFOX6.
This may be due to the unfavourable baseline characteristics of the
patients: more than half of the patients enrolled had peritoneal
seeding and three or more involved organs even though most of
the patients had good PS. Another reason for the failure could be
P* = 0.47
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Figure 2 Kaplan–Meier curves of time-to-progression (A) and overall survival (B) according to EGFR expression and serum ligand status. P-value by log-
rank test. Abbreviations: EGFR, epidermal growth factor receptor; EGF, epidermal growth factor; TGF, transforming growth factor.
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Abbreviations: EGFR, epidermal growth factor receptor; EGF, epidermal growth factor; TGF, transforming growth factor.
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sthe H1 set too high. In fact, the response rate and disease control
rate in this study is similar to those from cetuximab plus FOLFIRI
(44.1 and 91.2%, respectively) (Pinto et al, 2007). However, TTP
and OS are inferior to cetuximab plus FOLFIRI (Pinto et al, 2007).
In comparison with the recent three-drug combination chemo-
therapies, cetuximab plus mFOLFOX6 showed no better results in
terms of efficacy but with less toxicity, especially neutropenia
(Van Cutsem et al, 2006; Cunningham et al, 2008).
More importantly, the failure of improvement may be due to a
differential effect on the response rate from the addition of
cetuximab according to the molecular status of the tumour, as seen
with K-ras mutation and cetuximab plus FOLFOX in colorectal
cancer (Bokemeyer et al, 2008). Therefore, it is important to
identify who could benefit from cetuximab and who may be
potentially harmed by it in gastric cancer.
In the biomarker analysis, we have identified a subgroup of
patients that shows a more favourable outcome of who could be
the patients benefiting from cetuximab. Patients having EGFR
expression and low levels of the major ligands, EGF and TGF-a,
showed a 100% response rate. Considering the fact that cetuximab
is a monoclonal antibody that specifically targets EGFR and
competitively inhibits ligand binding, it is not unexpected that the
patients with tumour expression of EGFR and low levels of
competitive ligands showed better treatment outcome (Mendel-
sohn and Baselga, 2003). Elevation of ligand levels at the time of
disease progression further supports the important role of these
ligands in resistance to cetuximab treatment. High levels of serum
EGFR ligands have also been implicated in resistance to gefitinib in
lung cancer (Ishikawa et al, 2005). However, in colorectal cancer
patients receiving cetuximab, high gene expression of epiregulin
and amphiregulin in tumour was associated with better outcome
(Khambata-Ford et al, 2007; Tejpar et al, 2008a). It is likely that
different ligands may have distinct interactions with the various
EGFR targeting agents. It is also possible that different ligands may
have different roles within autocrine EGFR activation loop in
different cancers. As this study was a single arm phase II study,
whether the better outcome of the patients is a result of the
incorporation of cetuximab into the treatment, or is a consequence
of a possible innate good prognosis should be investigated in
future randomised studies.
There are limited but controversial reports regarding the
prognostic implication of EGFR expression in gastric cancer
(Gamboa-Dominguez et al, 2004; Lieto et al, 2008; Matsubara et al,
2008). In a recent study of cetuximab in gastric cancer which also
included EGFR-negative tumours, EGFR expression was not
associated with the response rate (Lordick et al, 2007). In contrast,
EGFR expression was an independent predictor of longer TTP in
the multivariate analysis in this study. Moreover, combined
analysis with serum ligand status further improved the selection
of patients having better outcomes. HER2 positive rate by IHC
(15.8%) or FISH (13.2%) is similar to previous reports considering
that all patients had gastric cancer and majority of patients had
diffuse type in the present study (Tanner et al, 2005; Leon-Chong
et al, 2007). In contrast to previous reports showing poor survival
of HER2-positive gastric cancer patients who underwent surgery,
HER2-positive patients showed a non-significant trend towards a
better outcome in this study (Allgayer et al, 2000; Tanner et al,
2005). HER2 may have a predictive role in cetuximab treatment of
gastric cancer. Low TP expression having association with better
OS is in accordance with previous studies which were performed in
gastrointestinal cancer patients who received 5-FU-based treat-
ments (Metzger et al, 1998; Napieralski et al, 2005).
The main limitation of this study was the sample size, which was
not large enough to test the differences between the statuses of
various biomarkers. Despite this, biomarkers were identified
which are independently associated with response or survival,
which we believe merit further investigation in randomised
studies.
In conclusion, cetuximab in combination with mFOLFOX6 as a
first-line treatment in gastric cancer showed the most promising
results in patients with EGFR expression and low serum ligand
levels (EGF and TGF-a). This combination treatment in gastric
cancer warrants further evaluation in a large-scale study with
biomarker analysis, including EGFR and ligand status, for future
optimisation of patient selection.
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